Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
BACKGROUND: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics, safety and efficacy of maraviroc in combination with optimized background therapy in treatmen...
Saved in:
Main Authors: | Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, Marinella Della Negra, Ismail Haroon Mitha, Jan Fourie, Annie Fang, Elna van der Ryst, Srinivas Rao Valluri, Manoli Vourvahis, Rebecca Yanhui Zhang-Roper, Charles Craig, Lynn McFadyen, Andrew Clark, Jayvant Heera |
---|---|
Other Authors: | ViiV Healthcare |
Format: | Article |
Published: |
2019
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/46736 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Pharmacokinetics and safety of maraviroc in neonates
by: Julia C. Rosebush, et al.
Published: (2022) -
CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus
by: Liu, J.X., et al.
Published: (2014) -
The role of tumour-expressed CCR6 and CCR7 in breast cancer metastasis and tumour immunity
by: Tang, Kai Xin
Published: (2020) -
Epigenetic modification of the human CCR6 gene is associated with stable CCR6 expression in T cells
by: Steinfelder, S., et al.
Published: (2016) -
Blockade of chemokine-induced signalling inhibits CCR5-dependent HIV infection in vitro without blocking gp120/CCR5 interaction
by: Grainger, D.J, et al.
Published: (2020)